Statement: Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial.
Primary_evidence: Adverse Events 1:   Total: 5/32 (15.63%)   Leukopenia 1/32 (3.13%)   Neutropenia 1/32 (3.13%)   Cataract 1/32 (3.13%)   Infection 1/32 (3.13%)   Upper respiratory tract infection 1/32 (3.13%)   Completed suicide 1/32 (3.13%)
Secondary_evidence: Adverse Events 1:   Total: 4/6 (66.67%)   Anemia  0/6 (0.00%)   Takotsubo cardiomyopathy  1/6 (16.67%)   Pericardial effusion  0/6 (0.00%)   Vertigo  1/6 (16.67%)   Retinal vein occlusion  0/6 (0.00%)   Gastroenteritis  1/6 (16.67%)   Vomiting  1/6 (16.67%)   Diarrhea  0/6 (0.00%)   Death  2/6 (33.33%)   Bile duct dilatation  0/6 (0.00%)   Hepatic hemorrhage  0/6 (0.00%) Adverse Events 2:   Total: 25/52 (48.08%)   Anemia  1/52 (1.92%)   Takotsubo cardiomyopathy  0/52 (0.00%)   Pericardial effusion  2/52 (3.85%)   Vertigo  0/52 (0.00%)   Retinal vein occlusion  1/52 (1.92%)   Gastroenteritis  0/52 (0.00%)   Vomiting  0/52 (0.00%)   Diarrhea  1/52 (1.92%)   Death  9/52 (17.31%)   Bile duct dilatation  1/52 (1.92%)   Hepatic hemorrhage  1/52 (1.92%)